2023 American Society of Hematology (ASH) Annual Meeting & Exposition
Speakers & Exhibition Booth
December 9-12, 2023
Read more
Photo: Canva
Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
Gastrointestinal Cancer
SCI member George Poultsides discusses his efforts to advance early detection of pancreatic cancer, improve personalized oncology, and direct Stanford's Surgical Oncology Fellowship program while enhancing patient-centered care.
Innovating the Early Detection of Pancreatic Cancer
Stanford Cancer Institute members Ash Alizadeh, MD, PhD, and Max Diehn, MD, PhD, have developed several novel techniques for early detection of cancer that rely on blood-based liquid biopsies.
CAR-T Cells and Cancer Therapeutics
The Cancer Therapeutics Program fosters collaboration across scientific and clinical disciplines in order to gain deeper insights into cancer’s underlying causes and develop more effective diagnostic, prognostic, and therapeutic approaches.
The Future of Cancer
The SCI is focused on pushing the limits of what we can do and what we know. The only way to really advance our knowledge is to push forward in laboratories, keep thinking about novel approaches, novel mechanisms. We cannot stand still!
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
-
Scar tissue holds hints about pancreatic cancer outcome, Stanford Medicine-led research finds
Pancreatic cancer is deadly, and its toll is growing. Scientists find that scar tissue around the tumor suggests how long a patient will live after diagnosis.
-
A new branch of oncology, cancer neuroscience, offers hope for hard-to-treat brain tumors
To drive their growth, many tumors hijack nervous system signals, including those needed for brain plasticity. Stanford Medicine discoveries are opening a promising new branch of oncology research.
-
Lung cancer screening guidelines perpetuate racial disparities, Stanford-led study finds
National guidelines for lung cancer screening are less effective for African Americans than for whites, Stanford study concludes. A risk-based analysis is more equitable and effective.
-
Lung cancer cells covertly thrive in brain under guise of protection, Stanford Medicine study finds
Small cell lung cancers often metastasize to the brain. A Stanford Medicine study shows they thrive there by emulating developing neurons and recruiting surrounding cells for protection.
Cancer Clinical Trials
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.